Repros Therapeutics Inc (RPRX)

[DewDiligence]

>…experienced and trustworthy CEOs do not say things like "slam dunk" with regard to ongoing clinical trials. Period.<

They do not use such a characterization for planned clinical trials either.

akasidney86 would have us believe that the existence of many zeros to the right of the decimal point in the p-value of an early-stage trial gives the CEO a license to prime investors by using the phrase slam dunk. This shows an astonishing naiveté about statistics and the biotech arena in general.

Right off the top of my head, I can think of two prominent drugs that had a long sequence of zeros to the right of the decimal point in their phase-3 p-values and yet almost didn’t make it to market. (Hint: one was rejected by an advisory panel and the other was rejected by a major regulatory body on the first review cycle.)